Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.57 |
| ▸ | POLB | P06746 | 8/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 17/20 | 0.56 |
| ▸ | MEN1 | O00255 | 16/20 | 0.56 |
| ▸ | RECQL | P46063 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3124645 | 1.00 | MAPT (0.57) | MAPTPOLBALDH1A1TDP1KDM4E | |
| SCHEMBL3131280 | 0.85 | MAPT (0.58) | MAPTPOLBALDH1A1TDP1KDM4E | |
| SCHEMBL3131303 | 0.85 | MAPT (0.58) | MAPTPOLBALDH1A1TDP1KDM4E | |
| SCHEMBL3138018 | 0.83 | IMPDH2 (0.46) | MAPTPOLBALDH1A1TDP1KDM4E | |
| SCHEMBL3123041 | 0.83 | MAPT (0.56) | MAPTPOLBALDH1A1TDP1KDM4E | |
| SCHEMBL3123056 | 0.83 | MAPT (0.56) | MAPTPOLBALDH1A1TDP1KDM4E | |
| SCHEMBL3131343 | 0.81 | MAPT (0.53) | MAPTPOLBALDH1A1TDP1KDM4E | |
| SCHEMBL3131353 | 0.81 | MAPT (0.53) | MAPTPOLBALDH1A1TDP1KDM4E | |
| SCHEMBL13272046 | 0.80 | IMPDH2 (0.39) | MAPTALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL13757053 | 0.75 | KMT2A (0.53) | MAPTPOLBALDH1A1TDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021333-B1 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S (IT) | 2010-07-14 | — | — | EP | claimed |
| EP-1860104-A1 | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof | Aptanomics (FR) | 2007-11-28 | — | — | EP | claimed |
| EP-2021333-B1 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S (IT) | 2010-07-14 | — | — | EP | disclosed |
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| EP-2021333-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS - Ethical Oncology Science S.p.A. (IT) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007135565-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
| EP-1860104-A1 | Anti-proliferative compounds deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof | Aptanomics (FR) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | MKI67, CCNA1, CCNI | MAPT 4821/4885POLB 3489/4885ALDH1A1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.